Bone marrow mesenchymal stem cells ameliorate neurological deficits and blood-brain barrier dysfunction after intracerebral hemorrhage in spontaneously hypertensive rats

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 4715-4724

  Wang, Chunyan ^a   Fei, Yiping ^a   Xu, Congshu ^a   Zhao, Yue ^b   Pan, Yujun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Department of Neurology Harbin Second Hospital   (China)

Author keywords

Blood brain barrier; Bone marrow mesenchymal stem cell; Intracerebral hemorrhage; Neurological function; Spontaneously hypertensive rats

Indexed keywords

ANIMAL; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; BRAIN; CEREBRAL HEMORRHAGE; CONVALESCENCE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BONE MARROW TRANSPLANTATION; BRAIN; CEREBRAL HEMORRHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTOR ACTIVITY; RATS; RATS, INBRED SHR; RECOVERY OF FUNCTION;

EID: 84937901189     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Keep RF, Hua Y and Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol 2012; 11: 720-731.
2. Wu G, Bao X, Xi G, Keep RF, Thompson BG and Hua Y. Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats. J Neurosurg 2011; 114: 1805-1811.
3. Minnerup J, Wagner DC, Strecker JK, Posel C, Sevimli-Abdis S, Schmidt A, Schilling M, Boltze J, Diederich K and Schabitz WR. Bone marrow-derived mononuclear cells do not exert acute neuroprotection after stroke in spontaneously hypertensive rats. Front Cell Neurosci 2014; 7: 288.
4. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009; 40: 510-515.
5. Ashton BA, Allen TD, Howlett CR, Eaglesom CC, Hattori A and Owen M. Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop Relat Res 1980; 294-307.
6. Pereira RF, Halford KW, O'Hara MD, Leeper DB, Sokolov BP, Pollard MD, Bagasra O and Prockop DJ. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 1995; 92: 4857-4861.
7. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M and Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005-1011.
8. Seo JH and Cho SR. Neurorestoration induced by mesenchymal stem cells: potential therapeutic mechanisms for clinical trials. Yonsei Med J 2012; 53: 1059-1067.
9. Lee ST, Chu K, Jung KH, Kim SJ, Kim DH, Kang KM, Hong NH, Kim JH, Ban JJ, Park HK, Kim SU, Park CG, Lee SK, Kim M and Roh JK. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. Brain 2008; 131: 616-629.
10. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW and Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643.
11. Meirelles Lda S, Fontes AM, Covas DT and Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20: 419-427.
12. Kopen GC, Prockop DJ and Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 1999; 96: 10711-10716.
13. Liu H, Honmou O, Harada K, Nakamura K, Houkin K, Hamada H and Kocsis JD. Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006; 129: 2734-2745.
14. Wislet-Gendebien S, Hans G, Leprince P, Rigo JM, Moonen G and Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005; 23: 392-402.
15. Ito M, Kuroda S, Sugiyama T, Maruichi K, Kawabori M, Nakayama N, Houkin K and Iwasaki Y. Transplanted bone marrow stromal cells protect neurovascular units and ameliorate brain damage in stroke-prone spontaneously hypertensive rats. Neuropathology 2012; 32: 522-533.
16. Calio ML, Marinho DS, Ko GM, Ribeiro RR, Carbonel AF, Oyama LM, Ormanji M, Guirao TP, Calio PL, Reis LA, Simoes Mde J, Lisboa-Nascimento T, Ferreira AT and Bertoncini CR. Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis, and hippocampal damage in brain of a spontaneous stroke model. Free Radic Biol Med 2014; 70: 141-154.
17. Tsai MJ, Tsai SK, Hu BR, Liou DY, Huang SL, Huang MC, Huang WC, Cheng H and Huang SS. Recovery of neurological function of ischemic stroke by application of conditioned medium of bone marrow mesenchymal stem cells derived from normal and cerebral ischemia rats. J Biomed Sci 2014; 21: 5.
18. Xue M and Del Bigio MR. Intracerebral injection of autologous whole blood in rats: time course of inflammation and cell death. Neurosci Lett 2000; 283: 230-232.
19. Chen J, Li Y, Wang L, Lu M, Zhang X and Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001; 189: 49-57.
20. Puurunen K, Jolkkonen J, Sirvio J, Haapalinna A and Sivenius J. An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology 2001; 40: 597-606.
21. Kunter U, Rong S, Djuric Z, Boor P, Muller-Newen G, Yu D and Floege J. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-2212.
22. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG and Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002; 20: 530-541.
23. Teixeira FG, Carvalho MM, Sousa N and Salgado AJ. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci 2013; 70: 3871-3882.
24. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D and Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytothe-rapy 2006; 8: 315-317.
25. Phinney DG and Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007; 25: 2896-2902.
26. Bianco P, Robey PG and Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319.
27. Yang Y and Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42: 3323-3328.
28. Keep RF, Zhou N, Xiang J, Andjelkovic AV, Hua Y and Xi G. Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage. Fluids Barriers CNS 2014; 11: 18.
29. Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013; 36: 437-449.
30. Bernacki J, Dobrowolska A, Nierwinska K and Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008; 60: 600-622.
31. Hawkins BT and Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
32. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S and Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993; 123: 1777-1788.
33. Wolburg H and Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002; 38: 323-337.
34. Yang Y, Estrada EY, Thompson JF, Liu W and Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709.
35. Summermann E, Huwer H and Seitz G. Carcinosarcoma of the lung, a tumour which has a poor prognosis and is extremely rarely diagnosed preoperatively. Thorac Cardiovasc Surg 1990; 38: 247-250.
36. Veltkamp R, Siebing DA, Sun L, Heiland S, Bieber K, Marti HH, Nagel S, Schwab S and Schwaninger M. Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. Stroke 2005; 36: 1679-1683.